The American defense technology company L3Harris (LHX.US) reported Q4 and full-year 2024 results, with annual sales at $21.3 billion, up 10% YoY and 4% organically quarterly expansion; record backlog at $34 billion and $24.2 billion in orders. Shares are up 2% after the report.
- Q4 2024 highlights include revenue of $5.5 billion up 3% YoY, operating margin of 10.3% with adjusted earnings per share of $3.47, surpassing above analyst consensus of $3.44
- L3Harris exceeded its cost-savings target for 2024, with $800 million through the LHX NeXt initiative; raising its overall cost-savings goal to $1.2 billion in FY 2025
- The company projects revenue at $21.8-22.2 billion in 2025 calendar year, with adj operating margin in the mid to high 15% range. The company expects Non-GAAP EPS of $10.55-10.85 and adjusted free cash flow at $2.4-2.5 billion.
- L3Harris reported fourth quarter adjusted earnings per share of $3.47, surpassing the analyst consensus of $3.44. Revenue for the quarter came in at $5.5 billion, in line with analyst expectations and up 3% YoY. The company noted that organic revenue growth was 4% for the quarter.
- L3Harris provided guidance for fiscal year 2025, projecting earnings per share between $10.55 and $10.85 and revenue in the range of $21.8 billion to $22.2 billion. The midpoint of the revenue guidance at $22 billion is slightly above the analyst consensus of $21.9 billion.
L3Harris (LHX.US, D1 interval)
L3Harris shares are still below EMA200 (red line), and even stronger than expected earnings, with US Iron Dome defense program, where L3Harris may be a beneficiary as well as RTX Corp (RTX.US) didn't lead to trend reversal in pre-market. The stock may open today session at $209.
Source: xStation5
Daily summary: Sentiments on Wall Street stall at the end of the week🗽US Dollar gains
AbbVie near 1-month low after earnings report 📉
Wall Street optimism tempers amid falling odds of December Fed rate cut
DE40: Decline of sentiment in Europe
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
